Japanese Encephalitis purified inactivated vaccine — Competitive Intelligence Brief

Japanese Encephalitis purified inactivated vaccine (Japanese Encephalitis purified inactivated vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Infectious Disease / Immunology.

phase 3 Inactivated viral vaccine Japanese encephalitis virus antigens Infectious Disease / Immunology Biologic

Target snapshot

Japanese Encephalitis purified inactivated vaccine (Japanese Encephalitis purified inactivated vaccine) — Valneva Austria GmbH. This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Japanese Encephalitis purified inactivated vaccine TARGET	Japanese Encephalitis purified inactivated vaccine	Valneva Austria GmbH	phase 3	Inactivated viral vaccine	Japanese encephalitis virus antigens
Sabin IPV + Sabin IPV + Sabin IPV	Sabin IPV + Sabin IPV + Sabin IPV	Zhejiang Provincial Center for Disease Control and Prevention	marketed	inactivated viral vaccine	poliovirus serotypes 1, 2, and 3
Havrix+Healive	Havrix+Healive	Sinovac Biotech Co., Ltd	marketed	Combination inactivated viral vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
2wIPV+1sIPV	2wIPV+1sIPV	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3 antigens
V - C - C+V	V - C - C+V	IlDong Pharmaceutical Co Ltd	marketed	Inactivated viral vaccine
Inactivated SARS-CoV-2 Vaccine (Vero cell）	Inactivated SARS-CoV-2 Vaccine (Vero cell）	Sinovac Research and Development Co., Ltd.	marketed	inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
IPV at 6 weeks of age	IPV at 6 weeks of age	Centers for Disease Control and Prevention	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

1. Sinovac Biotech Co., Ltd · 9 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
3. GlaxoSmithKline · 5 drugs in this class
4. Valneva Austria GmbH · 4 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Centers for Disease Control and Prevention · 3 drugs in this class
7. China National Biotec Group Company Limited · 2 drugs in this class
8. Statens Serum Institut · 2 drugs in this class
9. Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
10. Crucell Holland BV · 2 drugs in this class